ICER plots drug review topics for 2018

The US non-profit Institute for Clinical and Economic Review (ICER) has released its preliminary list of prescription drug review topics for 2018. The list of topics for review is drawn from ICER horizon scans of new and emerging therapies, conversations with stakeholders, and suggestions submitted from the public.

ICER’s  topic selection criteria – including the projected timing and likelihood of Food and Drug Administration approval, and whether a review of the evidence would suggest specific actions for payers, physicians, patients and policymakers to improve clinical practice and/or policy – are applied to produce a preliminary list of drugs for review.

The ICER aims to time reports so that they are released as close to FDA approval as possible. Due to the time required for each report (typically eight months), some of the drugs under consideration have not yet been submitted to the FDA for approval, but are expected to be filed in the near future. If submission plans or timing changes, alternate topics will be selected. Other than the two topics that have already been announced for the January and March 2018 public meetings, the following list is preliminary and subject to change: